QDENGA Dengue Vaccine Approved in India: Key Details, Dosage, and Benefits
QDENGA: Everything You Need to Know About India’s First Approved Dengue Vaccine
Dengue fever has long been one of India’s most persistent public health challenges. Every year, monsoon seasons bring a sharp surge in mosquito-borne infections, leading to high hospitalizations and severe strain on healthcare systems.
In a landmark decision, the Central Drugs Standard Control Organisation (CDSCO) and the Drug Controller General of India (DCGI) approved QDENGA (TAK-003), making it India’s first licensed dengue vaccine.
What Is QDENGA?
QDENGA is a live-attenuated tetravalent vaccine developed by Japanese pharmaceutical manufacturer Takeda.
How It Works
Tetravalent Protection: It is engineered using recombinant DNA technology to protect against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).
No Pre-Testing Required: Unlike earlier global dengue vaccines (such as Dengvaxia), QDENGA does not require blood testing to verify prior infection before administration.
Universal Eligibility: It can be given safely to people who have had dengue before, as well as those who have never been infected.
Key Highlights & Approval Summary
| Feature | Details |
| Vaccine Name | QDENGA® (TAK-003) |
| Manufacturer | Takeda Pharmaceuticals (Germany / India) |
| Approved Age Group | 4 to 60 years |
| Dose Schedule | 2 doses (0.5 mL subcutaneous injection, 3 months apart) |
| Pre-Vaccination Screening | Not required |
| Global Recognition | Approved in 40+ countries with World Health Organization (WHO) prequalification |
How Effective Is QDENGA?
Global clinical trials involving over 28,000 participants and dedicated Phase III safety trials in India demonstrated high efficacy and safety:
Hospitalization Prevention: Clinical data shows up to 84% reduction in dengue-related hospitalizations over 4.5 years of follow-up.
Symptomatic Disease Prevention: Reduces overall symptomatic dengue cases by approximately 61% to 80% depending on the virus strain.
Long-Term Safety: Post-marketing surveillance across tens of millions of doses globally confirms a strong safety profile with no major safety concerns.
Who Can Get the QDENGA Vaccine in India?
The vaccine is approved for children and adults between the ages of 4 and 60.
Important Note: QDENGA serves as an extra layer of defense against severe disease and hospital stay. However, health authorities emphasize that vaccination should complement—not replace—traditional mosquito control measures, such as removing standing water and using repellents.
Manufacturing and Availability in India
To ensure adequate supply and affordability, Takeda partnered with Hyderabad-based Biological E to manufacture up to 50 million doses annually in India. Local production helps build long-term supply resilience for both Indian domestic needs and global distribution.
Frequently Asked Questions (FAQs)
1. Does QDENGA prevent all cases of dengue?
No vaccine offers 100% protection against mild infection, but QDENGA significantly reduces the risk of getting sick and cuts the chances of severe illness or hospital admission by over 80%.
2. Do I need to get tested for dengue before taking the vaccine?
No. QDENGA does not require pre-vaccination antibody testing. It is safe for individuals regardless of their past dengue infection status.
3. How many doses are required?
The vaccination regimen consists of two separate injections given three months apart.
4. What are the common side effects?
Common side effects are generally mild and temporary, similar to other routine vaccines. They may include pain or redness at the injection site, mild fever, fatigue, or muscle aches.